MedTrace Logo

Human Umbilical Cord Mesenchymal Stem Cells Treatment in Sepsis

NCT06882811 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2025-05-25

No results posted yet for this study

Summary

The primary objective: To evaluate the efficacy of intravenous infusion of universal UC-MSCs and CD83+MSCs subpopulation injection in the treatment of sepsis by using the 28-day survival rate of the subjects as the primary efficacy criterion.The secondary objectives: 1. To systematically evaluate the safety of universal UC-MSCs and CD83+MSCs subpopulation in the treatment of sepsis; 2. To provide theoretical basis and clinical research data for establishing a safe, effective and feasible clinical treatment plan for sepsis using stem cells.

Conditions

Interventions

BIOLOGICAL

CD83-positive MSC

90 patients are infused with 1×10⁸ stem cells per session and receive regulatory treatment

BIOLOGICAL

regulatory MSC

45 patients are infused with 1×10⁸ stem cells per session and receive regulatory treatment

OTHER

control solution

45 patients are infused with equal volume of control solution and receive regulatory treatment

Sponsors & Collaborators

  • Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
0 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-22
Primary Completion
2027-12-31
Completion
2027-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06882811 on ClinicalTrials.gov